Nicholas Haft

Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY.

International Association for the Study of Pain operates as a professional forum for science, practice, and education in the field of pain. It brings together scientists, clinicians, health-care providers, and policymakers to stimulate and support the study of pain. The company was founded in 1973 and is headquartered in Washington, DC.

The Society for Neuroscience is an organization with over 36,000 members in more than 95 countries. The non-profit company is based in Washington. The organization also engages in science advocacy and public policy, including an annual Capitol Hill Day, and has various public outreach efforts, such as the interactive collection of public-facing resources on BrainFacts.org. It was founded in 1969 and offers year-round programming, including the publication of two scientific journals, professional development resources, and career training through Neuronline.

The American College of Neuropsychopharmacology provides a range of resources related to psychopharmacology and related fields. The non-profit company is based in Brentwood, TN. The company's Neuropsychopharmacology Reviews publication offers authoritative and timely coverage of contemporary topics in the field.

Avacen, Inc. provides non-invasive medical device that provides temporary relief for arthritis, muscle and joint pain. The company was founded by Thomas G. Muehlbauer and Danielle J Forsgren in 2008 and is headquartered in San Diego, CA.

IntroSpect Digital Therapeutics, Inc. provides digital therapeutic platform for mental health care and support. The firm is designed to extend the life changing potential of psychedelics-assisted psychotherapy to patients in a scalable way. The company was founded by David Keene, Srinivas G. Rao and Florian Brand and is headquartered in San Diego, CA.

ATAI Life Sciences AG operates as a holding company, which is a global biotech company builder. The company was founded by Christian Angermayer, Lars Christian Wilde, Srinivas G. Rao and Florian Brand in 2018 and is headquartered in Munich, Germany.

EntheogeniX Biosciences, Inc. is a biotech company located in Wilmington, DE. EntheogeniX Biosciences is dedicated to advancing psychedelic research for the development of better medicines for mental health diseases such as depression, bipolar disorder, and schizophrenia. The joint venture company aims to innovate the mental healthcare system by harnessing the power of artificial intelligence and computational biophysics, along with a data-driven pipeline, to uncover new medicines from desired psychedelics to further help patients. EntheogeniX Biosciences is a partnership between atai life sciences and Cyclica. The company was founded by Naheed Kurji and is currently led by CEO Srinivas G. Rao since 2019.

Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA.

Axial Therapeutics, Inc. provides biopharmaceuticals. It is harnessing the link between the human get microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders. The company was founded by Sarkis Mazmanian and David H. Donabedian and is headquartered in Boston, MA.

Perception Neuroscience, Inc. operates as a biopharmaceutical company, focusing on developing therapies in Neuropsychiatry. The company was founded by Jonathan Sporn and Jay Kranzler and is headquartered in New York, NY.

Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI.

Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA.

Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ.

nLife Therapeutics SL develops and manufactures pharmaceutical preparations. It specializes in oligonucleotides as therapeutic agents for central nervous system and neuromuscular disorders. The company was founded by Andres Pablo Montefeltro on September 24, 2009 and is headquartered in Armilla, Spain.

Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ.

Neuropore Therapies, Inc. provides biopharmaceutical services. It also offers alpha-synuclein (ASYN), amyloid beta, autophagy, and publications programs. The company was founded by Eliezer Masliah in 2008 and is headquartered in San Diego, CA.

Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million.

Sova Pharmaceuticals, Inc. engages in the discovery and development of human therapeutic drugs. It provides internal clinical plan on therapies supported by the mechanism, our preclinical findings, and the development of compounds reported to act on the molecular targets of H2S that include postherpetic neuralgia, chemotherapy induced peripheral neuropathic pain (CIPN pain) and diabetic neuropathy. The company’s pre-clinical findings support large-market indications, such as osteoarthritis, rheumatoid arthritis, neuropathic pain and migraine, that we would seek to develop with a strategic partner. The company was founded by Gary W. Pace and Solomon Snyder in 2010 and is headquartered in La Jolla, CA.